Establishment Labs (ESTA) FDA Approvals $70.03 -0.77 (-1.09%) As of 03:31 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Establishment Labs' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Establishment Labs (ESTA). Over the past two years, Establishment Labs has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Motiva. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Motiva Flora® SmoothSilk® FDA Regulatory Events Motiva Flora® SmoothSilk® is a drug developed by Establishment Labs for the following indication: Tissue Expander. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Approved - October 5,2026Approved Drug: Motiva Flora® SmoothSilk®Announced Date: October 5, 2026Indication: Tissue Expander.AnnouncementEstablishment Labs Holdings Inc announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States.AI SummaryEstablishment Labs Holdings Inc. said the U.S. Food and Drug Administration has approved 28 additional sizes of its Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants. The expanded U.S. range includes implants starting at 105 cc and offers more choices in volume, base width and projection across Mini, Demi and Full profiles. The approval adds 19 sizes to the Round line and nine to the Ergonomix line. New sizes range from 105 cc to 235 cc, depending on the product and profile. The company expects the expanded selection to be available in the United States before the end of the year. Establishment Labs said the broader range may help surgeons meet demand for smaller, more natural-looking results and better match implants to patients’ body frames and goals. A plastic surgeon quoted in the announcement said the added options can support subtle enhancements while allowing patients to use Motiva implants.Read Announcement Establishment Labs FDA Events - Frequently Asked Questions Has Establishment Labs received FDA approval? As of now, Establishment Labs (ESTA) has not received any FDA approvals for its therapy in the last two years. What drugs has Establishment Labs submitted to the FDA? In the past two years, Establishment Labs (ESTA) has reported FDA regulatory activity for Motiva Flora® SmoothSilk®. What is the most recent FDA event for Establishment Labs? The most recent FDA-related event for Establishment Labs occurred on October 5, 2026, involving Motiva Flora® SmoothSilk®. The update was categorized as "Approved," with the company reporting: "Establishment Labs Holdings Inc announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States." What conditions do Establishment Labs' current drugs treat? Currently, Establishment Labs has one therapy (Motiva Flora® SmoothSilk®) targeting the following condition: Tissue Expander.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Adagene FDA EventsAlnylam Pharmaceuticals FDA EventsGE HealthCare Technologies FDA EventsGenprex FDA EventsHUTCHMED FDA EventsOpus Genetics FDA EventsLigand Pharmaceuticals FDA EventsEthos Technologies Inc. Class A Common Stock FDA EventsRegeneron Pharmaceuticals FDA EventsTvardi Therapeutics FDA EventsBiohaven FDA EventsJohnson & Johnson FDA EventsActuate Therapeutics FDA EventsEnlivex Therapeutics FDA EventsImmuneering FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Teleflex FDA Events Haemonetics FDA Events MiniMed Group FDA Events Pulse Biosciences FDA Events TransMedics Group FDA Events AxoGen FDA Events NovoCure FDA Events PROCEPT BioRobotics FDA Events Alpha Tau Medical FDA Events Delcath Systems FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:ESTA last updated on 10/5/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersI wasn't planning on sharing this yet, but here it isMarkham Trading's complete Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 f...TradeWins | SponsoredChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredUnder 3 cents a nightBill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is ...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Establishment Labs Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Establishment Labs With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Approved - October 5,2026Approved Drug: Motiva Flora® SmoothSilk®Announced Date: October 5, 2026Indication: Tissue Expander.AnnouncementEstablishment Labs Holdings Inc announced that the U.S. Food and Drug Administration (FDA) has approved an expanded range of Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants for use in the United States.AI SummaryEstablishment Labs Holdings Inc. said the U.S. Food and Drug Administration has approved 28 additional sizes of its Motiva SmoothSilk® Round and Motiva SmoothSilk Ergonomix® breast implants. The expanded U.S. range includes implants starting at 105 cc and offers more choices in volume, base width and projection across Mini, Demi and Full profiles. The approval adds 19 sizes to the Round line and nine to the Ergonomix line. New sizes range from 105 cc to 235 cc, depending on the product and profile. The company expects the expanded selection to be available in the United States before the end of the year. Establishment Labs said the broader range may help surgeons meet demand for smaller, more natural-looking results and better match implants to patients’ body frames and goals. A plastic surgeon quoted in the announcement said the added options can support subtle enhancements while allowing patients to use Motiva implants.Read Announcement